Icalcaprant

Icalcaprant
Clinical data
Other names	CVL-354
Routes of; administration	Oral
Drug class	κ-Opioid receptor antagonist
Identifiers
	IUPAC name 4-[4-{{(2S)-2-(3-methoxy-1-methylpyrazol-4-yl)pyrrolidin-1-yl]methyl]phenoxy]benzamide;
CAS Number	2227384-17-8;
PubChem CID	134540598;
UNII	GNR4JZG668;
KEGG	D13002;
ChEMBL	ChEMBL5314519;
Chemical and physical data
Formula	C23H26N4O3
Molar mass	406.486 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C=C(C(=N1)OC)[C@@H]2CCCN2CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)N;
	InChI InChI=1S/C23H26N4O3/c1-26-15-20(23(25-26)29-2)21-4-3-13-27(21)14-16-5-9-18(10-6-16)30-19-11-7-17(8-12-19)22(24)28/h5-12,15,21H,3-4,13-14H2,1-2H3,(H2,24,28)/t21-/m0/s1; Key:OBDLEFCGVHQDFR-NRFANRHFSA-N;

Icalcaprant^[1] (developmental code name CVL-354) is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.^[2]^[3] It is taken by mouth.^[2]

It acts as a selective antagonist of the KOR.^[2]^[3] The drug is also more weakly an antagonist of the μ-opioid receptor (MOR), with about 31-fold lower affinity and 27-fold lower inhibitory potency at the MOR relative to the KOR.^[3]

It was originated by Pfizer and is under development by Cerevel Therapeutics (a subsidiary of AbbVie).^[2]^[4] As of September 2022, icalcaprant is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.^[2]

References

↑ "Icalcaprant (CVL-354)". AbbVie. Retrieved 2024-08-15.
1 2 3 4 5 "CVL 354 – Cerevel therapeutics". Adis Insight. Springer Nature Switzerland AG.
1 2 3 "ACNP 61st Annual Meeting: Poster Abstracts P271-P540". Neuropsychopharmacology. 47 (Suppl 1): 220–370. December 2022. doi:10.1038/s41386-022-01485-0. eISSN 1740-634X. PMC 9714399. PMID 36456694.
↑ "AbbVie Completes Acquisition of Cerevel Therapeutics". AbbVie News Center. Retrieved 2025-05-07.

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

[1] "Icalcaprant (CVL-354)". AbbVie. Retrieved 2024-08-15.

[AdisInsight-2] 1 2 3 4 5 "CVL 354 – Cerevel therapeutics". Adis Insight. Springer Nature Switzerland AG.

[Suidan2022-3] 1 2 3 "ACNP 61st Annual Meeting: Poster Abstracts P271-P540". Neuropsychopharmacology. 47 (Suppl 1): 220–370. December 2022. doi:10.1038/s41386-022-01485-0. eISSN 1740-634X. PMC 9714399. PMID 36456694.

[4] "AbbVie Completes Acquisition of Cerevel Therapeutics". AbbVie News Center. Retrieved 2025-05-07.

[1]

[2]

[3]

[4]

This page was redesigned at the edge.

Icalcaprant

See also

References